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Abstract: Evidence shows that weightloss improves insulin sensitivity but few studies have 13 
examined the effect of macronutrient composition independently of weight loss on direct measures 14 
of insulin sensitivity. We randomised 89 overweight or obese women to either a standard diet 15 
(StdD) that was intended to be low in fat and relatively high in carbohydrate (n=42) or to a 16 
relatively high protein (up to 30% of energy), relatively high fibre (>30g/day) diet (HPHFib) (n=47) 17 
for 10 weeks. Advice regarding strict adherence to energy intake goals was not given. Insulin 18 
sensitivity and secretion was assessed by a novel method - the Dynamic Insulin Sensitivity and 19 
Secretion Test (DISST). Although there were significant improvements in body composition and 20 
most cardiometabolic risk factors on HPHFib, insulin sensitivity was reduced by 19.3% (95% CI: 21 
31.8, 4.5%; p=0.013) in comparison with StdD. We conclude that the reduction in insulin sensitivity 22 
after a diet relatively high in both protein and fibre, despite cardiometabolic improvements, 23 
suggests insulin sensitivity may reflect metabolic adaptations to dietary composition for 24 
maintenance of glucose homeostasis, rather than impaired metabolism. 25 
Keywords: diet; dietary protein; dietary fibre; insulin sensitivity assessment; insulin sensitivity; 26 
insulin resistance; metabolic syndrome 27 
1. Introduction 28 
There is considerable evidence to show that weight loss can improve insulin sensitivity and 29 
reduce risk of diabetes and cardiovascular disease (CVD)[1,2]. Few studies, however, have examined 30 
the effect of diet intervention on direct measures of insulin sensitivity (IS), particularly in the context 31 
of weight maintenance. However there is a substantial body of literature to show that variations in 32 
the macronutrient composition of diets can modify the cardiometabolic abnormalities associated 33 
with insulin resistance (IR) and therefore reduce the risk of diabetes. Low fat, high carbohydrate 34 
diets have been shown to raise triglyceride (TG) and to reduce high density lipoprotein (HDL) 35 
concentrations [3] whereas carbohydrate restriction may have the opposite effect while also having a 36 
positive influence of low density lipoprotein (LDL) particle size[4]. High protein diets have become a 37 
popular approach to weight loss and body composition with increasing evidence showing modest 38 
benefit over standard protein, relatively high carbohydrate diets at least in the relatively short term 39 
(one to two years)[5].  An alternative approach to reducing the metabolic abnormalities associated 40 
with low fat, high carbohydrate diets is to modify the quality of the carbohydrate consumed. There 41 
is some experimental and much epidemiological evidence to suggest that high fibre (particularly 42 
soluble fibre), low glycemic index (GI) carbohydrates derived from minimally processed wholegrain 43 
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cereals, fruit, vegetables and legumes may improve insulin sensitivity, maintain glucose 44 
homeostasis, reduce postprandial insulin concentrations, and reduce blood pressure in comparison 45 
with refined and high GI carbohydrates[6]. 46 
The gold-standard method for assessing insulin sensitivity is the hyperinsulinemic euglycaemic 47 
clamp[7]. However the clamp is rarely used as it is technically difficult, expensive, time-consuming 48 
and thus highly trained clinicians are required to perform the test[8]. Numerous techniques have 49 
been developed to simplify the measurement of IS but this has been at the expense of reliability and 50 
reproducibility[7]. Therefore researchers have more frequently used surrogate indices of IS based on 51 
fasting blood parameters, such as the homeostatic model of assessment (HOMA)[9] and the 52 
McAuley[10] methods. Such methods have been developed to describe the relationship of IS to 53 
disease progression in longitudinal population studies but relatively poor reproducibility and 54 
reliability limits their usefulness for detecting dietary-induced changes in IS in clinical studies[8]. 55 
The Dynamic Insulin Sensitivity and Secretion Test (DISST) was developed to address these 56 
issues[11]. The DISST is a variation of the infrequently sampled, low dose insulin-modified 57 
intravenous glucose tolerance test (IM-IVGTT) that can simultaneously provide highly reproducible 58 
estimates of IS and beta cell function[11].  59 
The aim of this study was to examine the effect of a reduced carbohydrate diet that was 60 
moderately high in both protein and dietary fiber (HPHFib diet) on IS and insulin secretion using 61 
the DISST method in overweight and obese women, independently of weight loss. 62 
2. Materials and Methods  63 
2.1 Subjects and experimental protocol 64 
The subjects, study design and diets have been previously described [12]. In brief, 89 women at 65 
risk of diabetes, who met screening criteria, were randomly assigned to either a standard diet (StdD) 66 
or a relatively high protein and high fibre diet (HPHFib) for 10 weeks. Advice regarding strict 67 
adherence to energy intake goals was not given (i.e total energy intakes were ad libitum). 89 women 68 
were randomly assigned to treatment, 6 withdrew before receiving the allocated treatment, 8 69 
withdrew during the treatment period and 75 women completed the entire study. 70 
At baseline, week 4 and week 10 measurements of height, weight, waist circumference and 71 
seated blood pressure were taken and fasting blood samples were collected for the measurement of 72 
serum lipids, and plasma glucose and insulin (in vacutainers containing antiglycolytic and/or EDTA 73 
anticoagulants). A DISST test was then carried out. Body composition was measured by dual X-ray 74 
absorptiometry (DXA) at baseline and week 10 only.  75 
Each subject gave informed, written consent and all experimental procedures were approved 76 
by the University of Otago Human Ethics Committee (reference 06/182). The trial was registered 77 
with the Australian New Zealand Clinical Trials Registry (ACTRN12607000154404). 78 
 79 
2.2 Diets 80 
The standard diet (StdD) group received dietary advice based on the New Zealand Food and 81 
Nutrition Guidelines for Healthy Adults [13]. Dietary goals were for approximately 20% of total 82 
energy (TE) to be derived from protein, 50% from carbohydrate and 30% from total fat with <10% 83 
from saturated fat. Dietary fibre intake was to be ≥25g/d. The StdD group were given a resource 84 
available from the Ministry of Health in New Zealand designed to facilitate adherence to these 85 
guidelines, and a food group checklist which provided daily serving targets for major food groups. 86 
Tailored dietary advice based on these recommendations was delivered by the researcher during an 87 
individual 45-60 minute counselling session at week 0 and week 5. Participants were encouraged to 88 
make fortnightly appointments to monitor progress and discuss strategies for maintaining 89 
adherence to the diet, but this was not compulsory. 90 
The HPHFibe diet was designed to achieve 30%TE from protein, 50% from carbohydrate, 20% 91 
from fat, and a dietary fibre intake of ≥35g/d. Individuals were asked to increase their usual protein 92 
intake with lean meats, fish or low-fat dairy foods and to choose carbohydrates that were 93 
particularly high in soluble fibre such as oats, certain legumes, nuts, dried fruit and stone fruits as 94 
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well as wholegrain breads and cereals. Restriction of fat intake was necessary in order to achieve the 95 
dietary fibre and protein goals without increasing energy intakes or requiring a dietary fibre 96 
supplement. Consumption of refined carbohydrates including white bread, white rice, pasta, cakes, 97 
biscuits and scones was discouraged. The HPHFib group was given material especially prepared for 98 
this study, including recipes and sample diet plans, since relevant material was not readily available. 99 
Because the HPHFib diet would not have been familiar to the typical New Zealander participants 100 
were optionally provided with a variety of pre-prepared frozen main course meals especially 101 
formulated to be high in protein and fibre as well as 30g/d high protein whey concentrate powder 102 
(NZMP™ Whey Protein Concentrate 392, Fonterra Co-operative Group Limited, New Zealand), 103 
wholegrain breakfast cereal and bread, canned beans and canned fish. The high protein whey 104 
powder was supplied to enable participants to maintain a relatively conventional eating plan based 105 
around a cereal-based breakfast while also increasing protein intake. Tailored dietary advice based 106 
on these recommendations was delivered by the researcher during an individual 45-60 minute 107 
counselling session at week 0 and week 5. Participants met with the researcher on a weekly basis in 108 
subsequent weeks to monitor progress and discuss strategies for maintaining adherence to the diet. 109 
Thus the HPHFib group were provided with a more intensive treatment than the StdD group.  110 
For both groups, during the initial 4-week study phase, intensive advice was given regarding 111 
food choices necessary to achieve the required macronutrient composition while maintaining usual 112 
weight. During the following 6 weeks they were encouraged to continue the recommended dietary 113 
pattern. 114 
 Participants completed a weighed 3-day diet record including 2 non-consecutive weekdays 115 
and one weekend day prior to commencing the intervention and at week 8. Dietary intakes of 116 
various nutrients were calculated using the Diet Cruncher for Macintosh V1.2.0 program (Waydown 117 
South Software), which uses the New Zealand food composition database (Crop and Food New 118 
Zealand). Missing food items were obtained from manufacturers’ information or other published 119 
references. 120 
 121 
2.3 Insulin sensitivity measurements 122 
Insulin sensitivity and other risk factors associated with the metabolic syndrome were assessed 123 
at baseline, week 4 and week 10. Insulin sensitivity was assessed with by the DISST method, 124 
conducted by a research nurse under medical supervision. After a 10-12hr fast participants had a 125 
cannula inserted into the antecubital fossa. Blood samples were drawn at t = 0, 10, 15, 25, and 35 126 
minutes for measurement of plasma glucose, and serum insulin and C-peptide. A 10-g bolus of 127 
intravenous glucose was given at t = 5 minutes, and 1 U of Actrapid insulin was given immediately 128 
after the t = 15-minute sample.  129 
The DISST model estimates insulin sensitivity (SI), glucose distribution volume (Vg), and 130 
first-pass (xL) and subsequent hepatic insulin clearance (nL) and three metrics of β-cell function 131 
derived from insulin production profiles and C-peptide data[11] following the methods of Van 132 
Cauter et al[14,15]. The basal rate (Ub) indicates the rate of insulin production an individual requires 133 
to maintain blood glucose at fasting levels. The area under the curve (AUC10) measures the 134 
first-phase insulin production produced immediately after the glucose bolus. AUC2nd measures the 135 
individual's second phase of insulin production during the 20 minutes after the period measured by 136 
AUC10[11]. 137 
 138 
2.4 Laboratory Analyses 139 
Whole blood samples were centrifuged at 1650g for 15 minutes, then samples were pipetted 140 
into polyethylene cryovials and stored at -80°C. Laboratory results at all time-points for all subjects 141 
were performed in batch within the same assay. Serum insulin and C-peptide were measured using 142 
a specific insulin electrochemiluminescence immunoassay  (ECLIA) (Roche, Cat. No. 12017547) for 143 
the Elecsys® analyzer (Roche Diagnostics, Mannheim, Germany), with a coefficient of variation of 144 
1.5%. Serum total cholesterol (total-cholesterol and triglycerides (TG) concentrations were measured 145 
enzymatically with Roche kits and calibrators on a Cobas Mira analyzer, as was plasma glucose 146 
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(Roche Hexokinase Cat. No. 11447513216). Coefficients of variation were 2.8% for total-cholesterol, 147 
4.4% for TG and 0.5% for plasma glucose. HDL-cholesterol was measured in the supernatant after 148 
precipitation of apolipoprotein B containing lipoproteins with phosphotungstate/magnesium 149 
chloride solution [16] with a coefficient of variation of 3.6%. LDL-cholesterol was calculated using 150 
the Friedewald equation [(total-cholesterol – HDL-cholesterol – (TG / 2.18)] [17]. 151 
 152 
2.5 Analysis and Statistics 153 
Insulin resistance was estimated by HOMA-IR index using the HOMA-IR2 calculator [9] and by 154 
the McAuley index using fasting insulin and TG, where predicted insulin sensitivity is expressed as 155 
exponent (2.63 - 0.28 ln[fasting insulin] - 0.31 ln[fasting TG]) [10]. A McAuley index value ≤6.3 156 
indicated insulin resistance . 157 
The number of participants required to detect a 30% difference in insulin resistance as assessed 158 
by the HOMA-IR index with 80% power at level of significance of 0.05 was 72. Statistical analysis 159 
was performed using the STATA statistical software package 9.0 (Stata, College Station, TX). 160 
Baseline data are presented as mean (SD). Elsewhere data are presented as mean (SE) or as geometric 161 
means (min, max) for logarithmically transformed values. Data were analysed on a modified 162 
intention-to-treat basis (i.e. without imputation of missing values). A mixed model using 163 
“participant” as a random effect was used to analyse the effect of the treatment over the two 164 
intervention phases (weeks 0-4 and weeks 5-10) using baseline values as a covariate [18] (overall 165 
model). Interactions between time and diet were tested by including a term for “time*diet” in the 166 
model. Since there were significant interactions between time and diet for some biochemical 167 
variables the effect of treatment at week 4 and week 10 were estimated separately by analysis of 168 
covariance using baseline values as a covariate. The overall model is also presented for variables 169 
where there was no significant “time*diet” interaction. For dietary variables only the overall model 170 
is shown. This does not change the interpretation of the results but has a conservative effect on the 171 
power to show a statistical significance since the number of observations is decreased and the SE is 172 
increased with the separate analyses. 173 
 The estimates for all variables except for those relating to body composition have been further 174 
adjusted for baseline weight and change in weight during the intervention period. This is because 175 
the intention of the study was to assess the effect of macronutrient composition on insulin sensitivity 176 
independently of weight loss. Both unadjusted and adjusted models are presented. 177 
A post-hoc analysis was conducted to examine the DISST insulin sensitivity and insulin 178 
secretion models for interactions between insulin sensitivity status and diet group by including an 179 
interaction term for group*insulin resistance status. ISIclamp equivalent <1.0 e-2mg/kg/(pmol/L)/min was 180 
used to define insulin resistance. 181 
  182 
3. Results 183 
Table 1 presents the baseline characteristics of the participants who started the dietary intervention. 184 
More participants were initially randomised to the HPHFib group (44 vs. 39), they were slightly 185 
older and had a higher estimated prevalence of insulin resistance. There were 39 women in the 186 
HPHFib group and 37 women in the standard diet group for whom clinical and anthropometric data 187 
are reported.  188 
 189 
  190 
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Table 1. Baseline demographic and clinical details for all participants randomized to intervention 191 
 Standard diet group HPHFib Group 
n 39 44 
Age (years) 1 39 (18 – 65) 44 (21 – 61) 
BMI (kg/m2) 2 32.3 (5.1) 32.9 (5.5) 
Weight (kg) 2 89.1 (14.3) 87.8 (16.0) 
Systolic blood pressure (mm Hg) 2 






























 Never smoked 
 Former smoker 









On metformin 2 (5.1) 2 (4.5) 
On lipid lowering medications 3 (7.7) 3 (6.8) 
On blood pressure medications 4 (10.3 4 (9.1) 
Insulin resistance3 13 (33.3) 23 (52.3) 
DISST Insulin resistance4 31% 28% 
1 mean (range); 2 mean (SD); all other values are n (%); 3 defined by the McAuley method where Gffm/I ≤ 6.3 
G/mU/l; 4 ISIclamp equivalent < 1.0 e-2mg/kg/(pmol/L)/min - only calculated for participants for whom DISST data 
was also available at week 4 or week 10 (n=35 for StdD and n=39 for HPHFib) 
 192 
Baseline dietary macronutrient intakes were well matched (Table 2). Participants in HPHFib diet 193 
consumed significantly more protein and dietary fibre and less total fat and saturated fat than the 194 
StdD group during the study but there was no difference in total carbohydrate intake. Of the 195 
increase in total dietary fibre 38% was soluble fibre. On average HPHFib participants consumed 10.1 196 
(SE 13.5) g/d of whey protein powder providing 7.6 g/d protein. Legumes, lean mean and chicken, 197 
and fish provided the additional protein consumed by the HPHFib group. Reported energy intakes 198 
declined over the 10 weeks in both the control and HPHFib groups but there was no significant 199 
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Energy (kJ)       
StdD 8660 (2447) 7252 (1723) 7418 (1845) 0.0081   
HPHFib 8332 (2414) 7549 (1473) 7155 (1218) 0.0064 193 (-408, 794) 0.386 
Protein (% TE)       
StdD 18 (3) 21 (6) 19 (4) 0.6986   
HPHFib 18 (4) 25 (4) 24 (5) <0.0001 5.0 (3.2, 6.8) <0.0001 
Fat (% TE)       
StdD 32 (7) 28 (5) 30 (6) 0.4272   
HPHFib 31 (6) 25 (6) 25 (5) 0.0002 -4.5 (-6.8, -2.3) <0.0001 
Saturated fat (% 
TE) 
      
StdD 13 (4) 11 (3) 11 (3) 0.033   




      
StdD 45 (8) 47 (8) 46 (6) 0.8512   
HPHFib 46 (6) 45 (5) 45 (5) 0.8963 -1.7 (-4.3, 1.0) 0.211 
Dietary fibre 
(g/day) 
      
StdD 24 (7) 24 (8) 22 (7) 0.2023   
HPHFib 24 (6) 33 (9) 30 (7) 0.0004 9.6 (6.0, 13.1) <0.0001 
Soluble fibre 
(g/day) 
      
StdD 11 (3) 10 (3) 10 (4) 0.2454   
HPHFib 11 (4) 14 (4) 13 (3) 0.0874 3.6 (2.0, 5.1) <0.0001 
Insoluble fibre 
(g/day) 
      
StdD 13 (4) 13 (5) 12 (5) 0.2838   
HPHFib 12 (3) 18 (5) 16 (4) 0.0006 5.0 (2.9, 7.0) 0.0001 
1 P-value for difference between week 0 and week 10. 2As the time x group interaction effect was not 208 
significant a cross-sectional time-series regression model (xtreg) was used to obtain the estimate from week 4 209 
and week 10 measures. % TE = percentage of total daily energy intake. 210 
 211 
  212 
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Although the first 4 weeks of the study were intended to achieve weight-maintenance, at week 4 the 213 
HPHFib had lost a small amount of weight whereas the StdD had not changed. The difference 214 
between the groups was statistically significant. There was no further weight loss in the second 215 
phase of the study. Body composition was only measured at baseline and week 10. Total fat mass 216 
and truncal fat mass were lower in HPHFib than in StdD. Lean mass did not change in either group 217 
and there was no significant difference in waist circumference (Table 3).  218 
Table 3: Mean (SD) measures of body composition at baseline, week 41 and week 10 and adjusted differences 219 
between dietary groups 220 
 Standard diet HPHFib Difference between 







    
Baseline 89.2 (14.7) 85.4 (14.8)   
Week 4 89.0 (15.2) 84.2 (14.5) -1.3 (-1.8, -0.7) <0.0001 
Week 10 89.0 (15.1) 83.9 (14.5) -1.1 (-1.9, -0.3) 0.006 
     
Fat mass (kg)     
Baseline 40.9 (11.2) 39.1 (11.2)   
Week 10 41.2 (11.5) 38.1 (10.8) -1.0 (-1.8, -0.2) 0.014 
     
Fat mass (%)     
Baseline 45.8 (6.3) 45.6 (6.0)   
Week 10 46.2 (6.3) 45.0 (6.1) -0.6 (-1.30, 0.02) 0.059 
     
Trunkal fat mass (kg)    
Baseline 21 (6.7) 19.9 (6.0)   
Week 10 21.3 (6.9) 19.3 (5.8) -0.7 (-1.3, -0.1) 0.034 
     
Lean mass (kg)     
Baseline 44.3 (5.2) 42.5 (4.8)   
Week 10 43.9 (5.1) 42.4 (4.7) 0.1 (-0.5, 0.6) 0.843 
     
Waist circumference (cm)    
Baseline 96.6 (11.5) 94.5 (13.3)   
Week 4 95.6 (11.3) 93.2 (13.1) -0.8 (-2.3, 0.6) 0.266 
Week 10 
 
95.8 (12.0) 92.3 (12.6) -1.3 (-2.8, 0.2) 0.084 
1 DXA measures (fat and lean mass) were assessed at baseline and week 10 only 221 
2 A mixed model using “participant” as a random effect was used to estimate the effect of the treatment over the 222 
two intervention phases (weeks 0-4 and weeks 5-10) using baseline values as a covariate. As the time x group 223 
interaction effect was not significant a cross-sectional time-series regression model (xtreg) was used to obtain 224 
the overall estimate from week 4 and week 10 measures 225 
 226 
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In the unadjusted models DISST insulin sensitivity was reduced in the HPHFib group relative to the 227 
StdD group at both week 4 and week 10 but the difference between diets did not reach conventional 228 
levels of significance (Table 4). When DISST insulin sensitivity was adjusted for weight loss there 229 
was trend towards decreased insulin sensitivity at week 4 in the HPHFib group and a statistically 230 
significant decrease in insulin sensitivity at week 10. There was a statistically significant reduction in 231 
basal insulin secretion (Ub) in the HPHFib group compared with the StdD group at week 10 232 
although this was attenuated after adjustment for weight loss. There was a trend towards raised first 233 
phase insulin secretion (AUC5-15) in the HPHFib group (Table 4). In contrast fasting glucose was 234 
significantly lower at week 10 on the HPHFib diet in the unadjusted model and was bordering on 235 
significance in the model adjusted for weight loss. Insulin concentrations, HOMA-IR2, the McAuley 236 
insulin sensitivity index and SBP all showed a tendency towards improvement in the HPHFib group 237 
although none of these differences reached conventional levels of statistical significance and the 238 
effects were largely attenuated after adjustment for weight loss (Table 5).   239 
Post-hoc analyses testing for interaction effects between diet group, insulin sensitivity status and 240 
DISST metrics showed no significant difference between insulin sensitive and insulin resistant 241 
individuals (range of p-values: 0.084 to 0.723). This indicates that insulin sensitivity decreased in 242 
both insulin sensitive and insulin resistant individuals in the HPHFib group compared with those in 243 
the StdD group. However the interactions were close to statistical significance for AUC5-15 (p=0.086), 244 
U2nd (p=0.084) and Utotal (p=0.096) suggesting an increase in each measure of insulin secretion in 245 
insulin resistant individuals on HPHFib in comparison with StdD. The effects were: AUC5-15 +24.5% 246 
(95% CI: -4.1%, 48.8%); U2nd +14.2% (95% CI: -6.2%, 39.0%); and Utotal +11.9% (95% CI: -1.5%, 27.2%). In 247 
insulin sensitive individuals there were no differences. 248 
There was also generally an improvement in lipid concentrations in the HPHFib group whereas 249 
there was no change in the control group. Total cholesterol was lower at both week 4 and week 10 250 
even after adjustment for weight loss and this was significantly different to the StdD group in whom 251 
total-cholesterol increased. LDL-cholesterol was also reduced in the HPHFib group and the 252 
difference was significant at week 10 in the unadjusted model and bordered on significance in the 253 
adjusted model. On the other hand there was a small reduction in HDL-cholesterol at week 4 in the 254 
HPHFib group but this had improved by week 10. TG was reduced in the HPHFib group and 255 
unchanged in the StdD group but the difference was not significant (Table 6)256 
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 257 
Table 4: Geometric mean (min, max) DISST measures of insulin sensitivity and secretion at baseline, week 4 and week 10 and percentage differences between dietary groups 258 
adjusted for baseline values and weight change 259 
  Std diet HPHFib Difference between groups 
adjusted for baseline value1 
P-value Difference between 
groups adjusted for 





DISST IS (e-4L/pmol/min)       
Baseline 0.95 (0.33, 2.63) 0.97 (0.39, 2.61)     
Week 4 1.02 (0.38, 2.43) 0.91 (0.19, 2.47) -9.7% (-24.2%, 7.4%) 0.245 -13.6% (-29.5%, 6.1%) 0.16 
Week 10 0.98 (0.35, 3.14) 0.86 (0.25, 1.8) -13.4% (-26.4%, 2%) 0.084 -19.3% (-31.8%, -4.5%) 0.013 
Overall1   -12.1% (-23.5%, 1%) 0.069 -17.8% (-28.6%, -5.3%) 0.007 
       
Basal insulin secretion, Ub, (pmol/min)      
Baseline 215 (95, 380) 229 (94, 512)     
Week 4 205 (99, 384) 229 (109, 429) 1.3% (-6%, 9.3%) 0.727 6.4% (-2.4%, 16%) 0.154 
Week 10 218 (91, 444) 206 (88, 462) -12.1% (-20.4%, -2.9%) 0.012 -9.2% (-18.3%, 1%) 0.074 
Overall     Significant time*diet effect  
       
1st phase AUC insulin secretion, AUC5-15, (pmol)      
Baseline 4913 (1164, 16037) 5788 (2193, 13638)     
Week 4 4619 (1195, 14788) 6028 (1686, 15186) 11% (-2.1%, 25.8%) 0.101 9.4% (-5.5%, 26.7%) 0.223 
Week 10 4793 (1503, 13921) 5899 (2485, 16160) 6.9% (-3.8%, 18.8%) 0.209 7.2% (-4.1%, 19.9%) 0.216 
Overall   9.2% (-0.5%, 19.9%) 0.064 9.2% (-1.2%, 20.7%) 0.084 
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  Std diet HPHFib Difference between groups 
adjusted for baseline value1 
P-value Difference between 
groups adjusted for 





2nd phase AUC insulin secretion, U2nd, (pmol)      
Baseline 6143 (1588, 12350) 6388 (2750, 15932)     
Week 4 5919 (1850, 12631) 6470 (2269, 17434) 1.9% (-8.3%, 13.3%) 0.719 5% (-7.2%, 18.9%) 0.433 
Week 10 6088 (1933, 13892) 5969 (2238, 19210) -6% (-16.5%, 5.7%) 0.297 -6.6% (-17.9%, 6.2%) 0.29 
Overall   -2% (-11.2%, 8.1%) 0.688 -1.8% (-11.9%, 9.3%) 0.734 
       
Total insulin secretion, Utotal, (pmol/L)      
Baseline 15266 (7175, 27275) 16456 (6793, 37618)     
Week 4 14538 (7156, 25774) 16927 (8061, 39962) 5.4% (-1.6%, 12.9%) 0.133 7.1% (-1.2%, 16.2%) 0.096 
Week 10 15102 (7234, 27159) 15835 (6231, 43324) -3% (-10%, 4.4%) 0.411 -2.9% (-10.4%, 5.3%) 0.473 
Overall     Significant time*diet effect  
1 A mixed model using “participant” as a random effect was used to estimate the effect of the treatment over the two intervention phases (weeks 0-4 and weeks 5-10) using baseline 260 
values as a covariate. If the time x group interaction effect was not significant a cross-sectional time-series regression model (xtreg) was used to obtain the overall estimate from week 261 
4 and week 10 measures 262 
 263 
 264 







































 11 of 22 
 
Table 5: Geometric mean (min, max) measures of insulin sensitivity based on fasting blood samples at baseline, week 4 and week 10 and percentage differences between dietary 266 
groups adjusted for baseline values and weight change 267 
  Standard diet HPHFib Difference adjusted for 
baseline value1 
P value Difference adjusted for 





Fasting plasma glucose (mmol/L)      
Baseline 4.7 (3.8, 8.1) 4.7 (4.1, 5.7)     
Week 4 4.7 (3.6, 6.4) 4.6 (3.8, 5.9) -0.5% (-3.3%, 2.4%) 0.74 1.2% (-2%, 4.5%) 0.449 
Week 10 4.8 (3.9, 6.1) 4.6 (3.8, 5.8) -3.8% (-6.7%, -0.8%) 0.014 -3.1% (-6.3%, 0.1%) 0.057 
Fasting plasma insulin (pmol/L)      
Baseline 61.2 (18.8, 174.3) 77.5 (11.8, 729.9)     
Week 4 57.0 (13.2, 206.3) 66.1 (13.9, 190.3) -4.1% (-20.2%, 15.2%) 0.649 4.7% (-15.1%, 29.1%) 0.664 
Week 10 59.8 (20.8, 197.9) 63.4 (9, 206.3) -10% (-26.6%, 10.2%) 0.302 -2.1% (-21%, 21.3%) 0.844 
McAuley IS index       
Baseline 7.26 (3.3, 10.26) 6.69 (3.38, 14.23)     
Week 4 7.45 (3.6, 13.95) 7.15 (4.61, 11.89) 4.2% (-3.6%, 12.6%) 0.295 0.4% (-8.1%, 9.6%) 0.932 
Week 10 7.20 (3.55, 12.81) 7.30 (3.85, 15.26) 8.5% (-0.1%, 17.9%) 0.053 5.3% (-3.6%, 15%) 0.245 
HOMA-IR Index       
Baseline 1.28 (0.39, 3.69) 1.60 (0.24, 12.35)     
Week 4 1.19 (0.28, 4.18) 1.37 (0.29, 3.79) -4.4% (-20.2%, 14.5%) 0.621 4.4% (-15.1%, 28.3%) 0.68 
Week 10 1.26 (0.44, 4.08) 1.31 (0.18, 3.98) -11.2% (-27.3%, 8.4%) 0.24 -3.8% (-22.1%, 18.8%) 0.714 
1 A mixed model using “participant” as a random effect was used to estimate the effect of the treatment over the two intervention phases (weeks 0-4 and weeks 5-10) using 268 
baseline values as a covariate. As the time x group interaction effect was not significant a cross-sectional time-series regression model (xtreg) was used to obtain the overall 269 
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Table 6: Mean (SD) measures for other metabolic variables based on fasting blood samples and clinical measures at baseline, week 4 and week 10 and percentage differences between 271 
dietary groups adjusted for baseline values and weight change 272 
 Standard diet HPHFib Difference adjusted for 
baseline value1 
P value Difference adjusted for 
baseline value & weight 
change1 
P value 
Total cholesterol (mmol/L)       
Baseline 4.87 (1.45) 4.57 (0.82)     
Week 4 4.92 (1.58) 4.32 (0.82) -0.28 (-0.51, -0.04) 0.021 -0.25 (-0.48, -0.02) 0.031 
Week 10 5.03 (1.62) 4.36 (0.79) -0.40 (-0.66, -0.15) 0.002 -0.36 (-0.63, -0.09) 0.01 
LDL-cholesterol (mmol/L)       
Baseline 2.94 (1.00) 2.8 (0.74)     
Week 4 2.92 (0.89) 2.69 (0.77) -0.11 (-0.3, 0.09) 0.274 -0.15 (-0.37, 0.07) 0.173 
Week 10 3.00 (0.98) 2.66 (0.71) -0.25 (-0.48, -0.03) 0.029 -0.23 (-0.47, 0.01) 0.065 
HDL-cholesterol (mmol/L)       
Baseline 1.13 (0.29) 1.19 (0.34)     
Week 4 1.10 (0.28) 1.09 (0.28) -0.07 (-0.13, -0.02) 0.008 -0.07 (-0.13, -0.01) 0.032 
Week 10 1.12 (0.29) 1.17 (0.34) -0.02 (-0.09, 0.05) 0.534 -0.02 (-0.1, 0.05) 0.486 
Triglyceride (mmol/L)       
Baseline 1.42 (1.45) 1.32 (0.60)     
Week 4 1.37 (0.95) 1.21 (0.51) -0.09 (-0.28, 0.1) 0.351 -0.1 (-0.3, 0.09) 0.295 
Week 10 1.42 (1.03) 1.21 (0.68) -0.14 (-0.38, 0.11) 0.272 -0.09 (-0.35, 0.17) 0.506 
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 Standard diet HPHFib Difference adjusted for 
baseline value1 
P value Difference adjusted for 
baseline value & weight 
change1 
P value 
Baseline 120.7 (14.2) 118.7 (15.0)     
Week 4 124.1 (13.9) 117.0 (15.9) -3.8 (-11.0, 3.5) 0.299 -5.1 (-13.4, 3.1) 0.217 
Week 10 121.9 (15.0) 117.1 (12.8) -2.0 (-7.4, 3.4) 0.469 -1.5 (-7.2, 4.3) 0.607 
Diastolic BP (mm Hg)       
Baseline 77.8 (8.3) 78.2 (8.1)     
Week 4 76.1 (8.1) 75.2 (10.2) -0.78 (-5.3, 3.7) 0.972 -1.1 (-6.0, 3.8) 0.641 
Week 10 75.7 (8.1) 74.8 (8.0) -0.27 (-3.6, 3.1) 0.875 -0.1 (-3.6, 3.5) 0.972 
1 A mixed model using “participant” as a random effect was used to estimate the effect of the treatment over the two intervention phases (weeks 0-4 and weeks 5-10) using baseline 273 
values as a covariate. As the time x group interaction effect was not significant a cross-sectional time-series regression model (xtreg) was used to obtain the overall estimate from 274 
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4. Discussion 276 
This study showed that a modest increase in consumption of both dietary protein and fibre, 277 
without emphasis on energy reduction, improved several cardiometabolic risk factors in overweight 278 
women. There were modest reductions in body mass (1.2kg), total body fat (1.0kg) and central body 279 
fat (0.7kg) with no loss of lean mass and improvements in total serum and LDL-cholesterol 280 
concentrations. However insulin sensitivity, as measured by DISST, declined throughout the 281 
10-week study even during the first 4 weeks when moderate weight loss was achieved and 282 
compliance with the dietary goals was highest.  283 
Prospective analyses and lifestyle intervention studies indicate with remarkable consistency 284 
that high fibre diets are associated with a reduced risk of diabetes and CVD. Cross-sectional analyses 285 
of epidemiological studies using static measures of insulin sensitivity based on fasting 286 
concentrations of glucose and insulin such as the HOMA-IR index show a positive association 287 
between dietary fibre [19-21] or wholegrains[22,23] and insulin sensitivity. These findings are 288 
confirmed by cross sectional analyses using dynamic insulin and glucose stimulated models of 289 
insulin sensitivity including the frequently sampled intravenous glucose tolerance test [22] and the 290 
clamp [23]. Lifestyle intervention studies also provide evidence for a beneficial effect of dietary fibre 291 
from wholegrains, fruit and vegetables on insulin sensitivity [24,25] and reducing the risk of 292 
progression from IGT to diabetes [26-28]. However the effect of dietary fibre cannot be disentangled 293 
from the effect of other changes made in conjunction with lifestyle improvement.  294 
Various mechanisms have been proposed as to how dietary fibre might influence insulin 295 
sensitivity but there is as yet no definitive explanation. Refined carbohydrate foods are quickly 296 
absorbed and have hyperinsulinaemic and hyperglycaemic effects - both of which can lead to the 297 
down-regulation of GLUT 4 glucose transporters in peripheral tissues and a reduction in insulin 298 
sensitivity [29,30]. In contrast intact or minimally processed high fibre carbohydrate foods and those 299 
with a low glycaemic index (GI) are typically more slowly digested and absorbed resulting in 300 
reduced glycaemic and insulinaemic responses [31]. In addition the fermentation of indigestible 301 
dietary fibre in the colon produces short-chain fatty acids which may also regulate glucose 302 
homeostasis by inhibiting hepatic glucose production, stimulating hepatic glucose storage through 303 
glycogen synthesis and improving peripheral insulin sensitivity [32].  304 
A relatively small number of clinical trials involving healthy, overweight, insulin resistant and 305 
diabetic patients have shown that wholegrain-rich, high fibre diets can improve insulin sensitivity 306 
and glucose metabolism using direct methods of assessing insulin sensitivity relative to diets with 307 
low-fibre diets or those based on refined grains[33-36] but the evidence is inconsistent[37]. Acute 308 
studies comparing the effect of high fibre breads with lower fibre breads are equally conflicting 309 
[38,39]. However there is no evidence to suggest that high fibre diets impair insulin sensitivity. 310 
Studies examining the effect of GI on glucose homeostasis and direct measurements of insulin 311 
sensitivity have also not shown conclusive benefits of low GI diets compared with high GI diets. A 312 
carefully designed crossover study by Järvi and colleagues compared two identical diets differing 313 
only in GI in subjects with T2DM [40]. Insulin sensitivity measured by the clamp increased during 314 
both phases but there was no effect of GI. However day-long glucose and insulin responses and lipid 315 
profile were significantly reduced on the low GI diet compared with the high GI diet. Another study 316 
altering the GI and dietary fibre content of bread in premenopausal women with IGT and a history 317 
of gestational diabetes, showed no effect of GI on insulin sensitivity[41]. However compared with 318 
the high GI diet insulin responses to an intravenous glucose tolerance challenge reduced while 319 
glucose tolerance was maintained on the low GI diet suggesting an improvement in glucose 320 
metabolism. In contrast Kiens and Richter reported reduced insulin sensitivity (measured with the 321 
clamp) in healthy, lean men following a low GI diet compared with an isoenergetic high GI diet [42]. 322 
Dietary fibre was higher on the low GI diet and sucrose was substantially higher on the high GI diet. 323 
After the first week plasma glucose and insulin concentrations were reduced on the low GI diet but 324 
by day 30 there were no differences between the diets. Though limited and based on heterogeneous 325 
groups of subjects this evidence is contrary to the mechanistic evidence suggesting low GI diets 326 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 8 November 2017                   doi:10.20944/preprints201711.0055.v1
 15 of 22 
 
might improve insulin sensitivity. In fact low GI diets appear to reduce insulin sensitivity when 327 
measured with direct methods such as the clamp even though other aspects of glucose metabolism 328 
appear to be enhanced. This evidence is compatible with the findings of our study. 329 
Few appropriately designed studies have investigated the effect of high-protein diets on insulin 330 
sensitivity using direct methods of assessment. Dietary interventions comparing HP and high 331 
carbohydrate (HC) diets designed to achieve weight loss of approximately 5% or more of total body 332 
weight suggest that HP diets may improve glucose metabolism and insulin sensitivity. A 3-wk 333 
weight loss trial in obese women that compared HP and HC diets found no change in insulin 334 
sensitivity (measured by the clamp) on the HP diet but a 30% decline in insulin sensitivity on the HC 335 
diet despite both diets achieving significant weight loss [43]. In adults with T2DM improved steady 336 
state insulin sensitivity (measured by a 150 min low-dose glucose and insulin infusion test) was 337 
shown on a HP diet compared with a high carbohydrate diet [44]. A HP diet was also associated 338 
with better glycaemic control than was a high carbohydrate diet in subjects with T2DM[45], while in 339 
obese, hyperinsulinaemic adults a 16-week moderate protein diet lowered postprandial glucose and 340 
insulin responses relative to a HC diet[46]. However substantial weight loss achieved in each of 341 
these studies may also explain the improvements in insulin sensitivity and glycaemic response[47]. 342 
In studies not involving weight loss, increased dietary protein intake has been associated with a 343 
reduction in insulin sensitivity and alterations in glucose metabolism that appear to be unfavourable 344 
[48,49]. An observational study showed that adults who habitually consume high-protein diets 345 
(>0.8g protein/kg/d) have reduced insulin sensitivity, lower rates of glucose oxidation, greater 346 
endogenous glucose production and greater net gluconeogenesis than those consuming low protein 347 
diets (<0.8g/kg/d)[50]. Subsequently a large randomised trial comparing weight maintaining diets in 348 
overweight adults has found reduced insulin sensitivity (measured by the clamp) in those following 349 
a HP diet compared with those on a HC diet that was high in cereal fibre after 6 weeks. However 350 
these differences were attenuated after 18 weeks, possibly as a result of decreased adherence to the 351 
HP diet[51] or effects of changes in amino acid metabolism [49]. In contrast two recent studies 352 
comparing HP diets with either a standard protein diet matched for carbohydrate intake[52] or a HC 353 
diet[53] found no differences in insulin sensitivity after four to six weeks under weight maintenance 354 
conditions. This suggests that carbohydrate quality may be more influential with regard to insulin 355 
sensitivity than the quantity of dietary protein or carbohydrate. Nevertheless there is mechanistic 356 
evidence giving weight to the suggestion that excessive protein consumption could lead to impaired 357 
insulin sensitivity and glucose metabolism40, 43. In humans an increase in plasma amino acid 358 
concentrations (by intravenous infusion) has been shown to cause a reduction in insulin-stimulated 359 
peripheral glucose uptake by inhibiting glucose transport[54,55] while cell-culture studies also 360 
demonstrate that excess amino acids inhibit glucose transport and suppress insulin-mediated 361 
inhibition of hepatic gluconeogenesis [56].  362 
However Layman and Baum [57] propose that one effect of dietary protein on glucose 363 
metabolism is the stabilization of blood glucose concentrations when protein intakes are high. 364 
Dietary protein is more slowly metabolized than dietary carbohydrate resulting in lower 365 
postprandial glucose and insulin responses after a high protein meal compared with a high 366 
carbohydrate meal [58,59]. Therefore while a HC diet necessitates rapid insulin responses and 367 
corresponding rapid peripheral uptake of glucose to maintain acceptable blood glucose 368 
concentrations, it follows that a HP, reduced carbohydrate diet may require a modulation of 369 
peripheral glucose uptake to maintain glucose homeostasis and prevent hypoglycaemia[57]. The 370 
brain uses glucose almost exclusively as a fuel source and a constant supply of blood glucose is 371 
critical to sustain brain activity [60]. However high concentrations of glucose are toxic and thus 372 
glucose must be tightly regulated [60]. Muscle is the principal site of insulin-stimulated glucose 373 
disposal in the body and glucose transport into skeletal muscle is the rate-controlling step in glucose 374 
metabolism [30]. The rate of glucose transport is likely to be determined by the expression and 375 
activity of proteins involved in the signalling pathways regulating the translocation of GLUT-4 from 376 
intracellular vesicles to the plasma membrane[30]. In individuals with insulin resistance the 377 
regulation of GLUT-4 may be inappropriate in response to abnormal circulating levels of a wide 378 
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range of factors including excess free fatty acids, glucose and cytokines [30]. Glucose transport may 379 
also be regulated by metabolites that act as cellular fuel sensors such as AMPK – a protein kinase, 380 
which is regulated by changes in the cellular ratio of AMP to ATP [61]. An observational study by 381 
Harber and colleagues provides interesting evidence of the capacity of the metabolic system to adapt 382 
to changes in the nature of the fuel supply [62]. In this study subjects were fed a 383 
very-low-carbohydrate diet (5% carbohydrate, 65% fat, 30% protein) for seven days. Such severe 384 
dietary carbohydrate restriction required marked metabolic adaptions to prevent hypoglycaemia. 385 
After 2 days post-absorptive glucose concentrations were reduced from baseline. However from day 386 
3 until the end of the study glucose returned to normal levels suggesting an adaptation to the to the 387 
diet had occurred in order to maintain glucose homeostasis. Using isotope dilution methods the 388 
researchers determined that peripheral glucose uptake was decreased for the duration of the study 389 
while glucose oxidation was reduced by 43% and the rate of non-oxidative glucose uptake (i.e. for 390 
storage as glycogen) was increased. A decrease in 24-hr insulin concentrations was observed which 391 
may have contributed to increased hepatic glucose production by stimulating gluconeogenesis and 392 
lipolysis.  393 
Participants on the HPHFib diet in this study increased their absolute protein intakes as well as 394 
intakes of high fibre, minimally processed carbohydrates. Although we did not measure 395 
postprandial glucose responses, the meals consumed by those on the HPHFib would have been 396 
more slowly absorbed than StdD meals thus leading to a more stable glycaemic environment and 397 
less reliance on rapid postprandial insulin-stimulated, peripheral glucose disposal during the 398 
10-week intervention. Therefore on the HPHFib diet peripheral it is conceivable that glucose 399 
transport was down-regulated to prevent hypoglycaemia[63]. Based on our observations we 400 
propose that after the intravenous glucose administration during the DISST, glucose uptake in 401 
peripheral tissues in the HPHFib group could not occur as rapidly as in the StdD group due to a 402 
diet-induce adaptation to a slower rate of glucose arrival in the blood. In conjunction with a decrease 403 
in the rate of glucose uptake there would be a temporary rise in plasma glucose concentrations 404 
resulting in an increase in first phase insulin secretion (AUC5-15). 405 
Although we propose that the reduction in DISST insulin sensitivity we observed with the 406 
HPHFib diet, after adjusting for the greater weightloss achieved, may not be indicative of 407 
impairment, prospective studies have shown associations between high protein intakes (particularly 408 
animal protein) and increased risk of diabetes[64-66]. However, in population studies high protein 409 
intakes may be associated with less healthy eating patterns including greater intakes of total energy, 410 
saturated fat and refined carbohydrates and lower intakes of protective foods such fruit, vegetables 411 
and wholegrains. Prospective studies are also particularly subject to reporting bias as subjects tend 412 
to under-estimate intakes of foods deemed undesirable and over-estimate intakes of food perceived 413 
to be healthy[67]. Dietary intervention studies investigating high-protein diets, in contrast, 414 
consistently show that in overweight or obese individuals at risk of diabetes HP diets result in 415 
greater weightloss (whether intentional or not) and associated improvements to a range of 416 
cardiometabolic risk factors than traditionally recommended low-fat, high-carbohydrate 417 
diets[68,69].  418 
The use of the novel DISST method to directly assess insulin sensitivity and secretion is a 419 
strength of this study. The DISST method correlates extremely well with the gold standard 420 
euglycaemic clamp and will generate diagnostic insulin sensitivity values with much greater 421 
sensitivity and specificity than values generated by crude index indices based on fasting blood 422 
parameters, such as HOMA-IR[9] and the McAuley method[10]. Although DISST has not previously 423 
been used to assess the effects of dietary change we believe it may be a superior test to the clamp, 424 
measuring insulin sensitivity in a more physiologically representative state and providing 425 
information on insulin secretion dynamics. 426 
5. Conclusion 427 
Insulin sensitivity measured by the novel DISST method was reduced in overweight women at risk 428 
of diabetes following an ad-libitum high protein, high fibre diet compared with those following a 429 
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standard ad-libitum high-carbohydrate, low-fat diet after accounting for weight loss differences. 430 
However there was a corresponding improvement in body composition and conventional 431 
cardiometabolic risk factors including static indices of insulin sensitivity. Therefore we propose that 432 
dynamic insulin sensitivity indicators may reflect metabolic adaptations to usual dietary intakes for 433 
maintenance of glucose homeostasis rather than an increase in risk of diabetes, and question their 434 
validity in dietary intervention studies. Further studies are required to explain and verify these 435 
effects. The cardiometabolic benefits achieved with moderate increases to fibre and protein, without 436 
emphasis on energy reduction support the use of this approach for overweight individuals at risk of 437 
diabetes. 438 
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